Shots:

• The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1-800 patients with moderate-to-severe plaque psoriasis across 200 sites WW
• reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%)- PASI 100 (29%); well tolerated; low AEs & discontinuation rates
• Ilumetri (tildrakizumab- SC- 100mg- q3mt) is a mAb targeting interleukin IL 23 p19 with its expected NICE approval in Apr’19. It has also received EU approval in Sept’18- codeveloped & co commercialize by Almirall & Sun Pharma under an agreement July’16

Ref: Almirall | Image: Okdiario